Cargando…
V-Raf murine sarcoma viral oncogene homolog B1 (BRAF) as a prognostic biomarker of poor outcomes in esophageal cancer patients
BACKGROUND: Esophageal cancer is one of the most aggressive malignancies, and is associated with multiple genetic mutations. At present, the v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) gene mutation has been observed in esophageal cancer and is associated with poor prognosis. This study ai...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903799/ https://www.ncbi.nlm.nih.gov/pubmed/33622273 http://dx.doi.org/10.1186/s12876-021-01671-2 |
_version_ | 1783654807736680448 |
---|---|
author | Kuerbanjiang, Aihemaijiang Maimaituerxun, Maimaitiyiming Zhang, Yanjun Li, Yiliang Cui, Gang Abuduhabaier, Aibaidula Aierken, Abuduwaili Miranbieke, Buya Anzaer, Meilikezati Maimaiti, Yusufu |
author_facet | Kuerbanjiang, Aihemaijiang Maimaituerxun, Maimaitiyiming Zhang, Yanjun Li, Yiliang Cui, Gang Abuduhabaier, Aibaidula Aierken, Abuduwaili Miranbieke, Buya Anzaer, Meilikezati Maimaiti, Yusufu |
author_sort | Kuerbanjiang, Aihemaijiang |
collection | PubMed |
description | BACKGROUND: Esophageal cancer is one of the most aggressive malignancies, and is associated with multiple genetic mutations. At present, the v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) gene mutation has been observed in esophageal cancer and is associated with poor prognosis. This study aimed to investigate the protein expression of BRAF in esophageal cancer and determine its effect on patient outcomes. METHODS: We used immunohistochemistry to detect the expression of BRAF via tissue microarrays in esophageal cancer samples, the Kaplan–Meier method to perform survival analysis, and the Cox proportional hazards regression model to explore the risk factors of esophageal cancer. The role of BRAF in the proliferation, invasion, and metastasis of esophageal cancer was studied by clone formation, scratch test, Transwell invasion and migration test. The tumor-bearing model of BRAF inhibitor was established using TE-1 cells, and corresponding negative control was set up to observe the growth rate of the two models. RESULTS: The results revealed that BRAF overexpression was significantly correlated with Ki67 (P < 0.05). Survival analysis showed that BRAF overexpression contributed to a shorter overall survival (P = 0.014) in patients with esophageal cancer. Univariate and multivariate regression analyses demonstrated that BRAF was a prognostic factor for poor esophageal cancer outcomes (P < 0.05). Small interfering RNA knockdown of BRAF significantly reduced the cell clone formation rate compared to the control group. Transwell assay analysis showed that the migration and invasion of cells in the experimental group were significantly inhibited relative to the control group, and the inhibition rates of the small interfering RNA group were 67% and 60%, respectively. In the scratch test, the wound healing ability of the BRAF knockdown group was significantly weaker than that of the control group. There were significant differences in tumor growth volume and weight between the two groups in nude mice. CONCLUSION: BRAF overexpression may serve as an effective predictive factor for poor prognosis. |
format | Online Article Text |
id | pubmed-7903799 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-79037992021-02-25 V-Raf murine sarcoma viral oncogene homolog B1 (BRAF) as a prognostic biomarker of poor outcomes in esophageal cancer patients Kuerbanjiang, Aihemaijiang Maimaituerxun, Maimaitiyiming Zhang, Yanjun Li, Yiliang Cui, Gang Abuduhabaier, Aibaidula Aierken, Abuduwaili Miranbieke, Buya Anzaer, Meilikezati Maimaiti, Yusufu BMC Gastroenterol Research Article BACKGROUND: Esophageal cancer is one of the most aggressive malignancies, and is associated with multiple genetic mutations. At present, the v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) gene mutation has been observed in esophageal cancer and is associated with poor prognosis. This study aimed to investigate the protein expression of BRAF in esophageal cancer and determine its effect on patient outcomes. METHODS: We used immunohistochemistry to detect the expression of BRAF via tissue microarrays in esophageal cancer samples, the Kaplan–Meier method to perform survival analysis, and the Cox proportional hazards regression model to explore the risk factors of esophageal cancer. The role of BRAF in the proliferation, invasion, and metastasis of esophageal cancer was studied by clone formation, scratch test, Transwell invasion and migration test. The tumor-bearing model of BRAF inhibitor was established using TE-1 cells, and corresponding negative control was set up to observe the growth rate of the two models. RESULTS: The results revealed that BRAF overexpression was significantly correlated with Ki67 (P < 0.05). Survival analysis showed that BRAF overexpression contributed to a shorter overall survival (P = 0.014) in patients with esophageal cancer. Univariate and multivariate regression analyses demonstrated that BRAF was a prognostic factor for poor esophageal cancer outcomes (P < 0.05). Small interfering RNA knockdown of BRAF significantly reduced the cell clone formation rate compared to the control group. Transwell assay analysis showed that the migration and invasion of cells in the experimental group were significantly inhibited relative to the control group, and the inhibition rates of the small interfering RNA group were 67% and 60%, respectively. In the scratch test, the wound healing ability of the BRAF knockdown group was significantly weaker than that of the control group. There were significant differences in tumor growth volume and weight between the two groups in nude mice. CONCLUSION: BRAF overexpression may serve as an effective predictive factor for poor prognosis. BioMed Central 2021-02-23 /pmc/articles/PMC7903799/ /pubmed/33622273 http://dx.doi.org/10.1186/s12876-021-01671-2 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Kuerbanjiang, Aihemaijiang Maimaituerxun, Maimaitiyiming Zhang, Yanjun Li, Yiliang Cui, Gang Abuduhabaier, Aibaidula Aierken, Abuduwaili Miranbieke, Buya Anzaer, Meilikezati Maimaiti, Yusufu V-Raf murine sarcoma viral oncogene homolog B1 (BRAF) as a prognostic biomarker of poor outcomes in esophageal cancer patients |
title | V-Raf murine sarcoma viral oncogene homolog B1 (BRAF) as a prognostic biomarker of poor outcomes in esophageal cancer patients |
title_full | V-Raf murine sarcoma viral oncogene homolog B1 (BRAF) as a prognostic biomarker of poor outcomes in esophageal cancer patients |
title_fullStr | V-Raf murine sarcoma viral oncogene homolog B1 (BRAF) as a prognostic biomarker of poor outcomes in esophageal cancer patients |
title_full_unstemmed | V-Raf murine sarcoma viral oncogene homolog B1 (BRAF) as a prognostic biomarker of poor outcomes in esophageal cancer patients |
title_short | V-Raf murine sarcoma viral oncogene homolog B1 (BRAF) as a prognostic biomarker of poor outcomes in esophageal cancer patients |
title_sort | v-raf murine sarcoma viral oncogene homolog b1 (braf) as a prognostic biomarker of poor outcomes in esophageal cancer patients |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903799/ https://www.ncbi.nlm.nih.gov/pubmed/33622273 http://dx.doi.org/10.1186/s12876-021-01671-2 |
work_keys_str_mv | AT kuerbanjiangaihemaijiang vrafmurinesarcomaviraloncogenehomologb1brafasaprognosticbiomarkerofpooroutcomesinesophagealcancerpatients AT maimaituerxunmaimaitiyiming vrafmurinesarcomaviraloncogenehomologb1brafasaprognosticbiomarkerofpooroutcomesinesophagealcancerpatients AT zhangyanjun vrafmurinesarcomaviraloncogenehomologb1brafasaprognosticbiomarkerofpooroutcomesinesophagealcancerpatients AT liyiliang vrafmurinesarcomaviraloncogenehomologb1brafasaprognosticbiomarkerofpooroutcomesinesophagealcancerpatients AT cuigang vrafmurinesarcomaviraloncogenehomologb1brafasaprognosticbiomarkerofpooroutcomesinesophagealcancerpatients AT abuduhabaieraibaidula vrafmurinesarcomaviraloncogenehomologb1brafasaprognosticbiomarkerofpooroutcomesinesophagealcancerpatients AT aierkenabuduwaili vrafmurinesarcomaviraloncogenehomologb1brafasaprognosticbiomarkerofpooroutcomesinesophagealcancerpatients AT miranbiekebuya vrafmurinesarcomaviraloncogenehomologb1brafasaprognosticbiomarkerofpooroutcomesinesophagealcancerpatients AT anzaermeilikezati vrafmurinesarcomaviraloncogenehomologb1brafasaprognosticbiomarkerofpooroutcomesinesophagealcancerpatients AT maimaitiyusufu vrafmurinesarcomaviraloncogenehomologb1brafasaprognosticbiomarkerofpooroutcomesinesophagealcancerpatients |